Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
Clene announces evidence from post-hoc analysis of HEALY ALS platform trial
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
Mitsubishi Tanabe Pharma America to Showcase New Research Findings in ALS at 2025 MDA Clinical and Scientific Conference
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...
Le Lézard17h
Hiscox UK Goes Live with Sapiens Insurance Platform on Sapiens Cloud
Sapiens International Corporation,  , a leading global provider of software solutions for the insurance industry, announced today that Hiscox, a leading insurer of tailored solutions for both ...